'Molecular targets' diaporamas de présentation

Molecular targets - PowerPoint PPT Presentation

CURCUMIN FROM TURMERIC AS A DRUG CANDIDATE FOR ALZHEIMER’S DISEASE

CURCUMIN FROM TURMERIC AS A DRUG CANDIDATE FOR ALZHEIMER’S DISEASE

CURCUMIN FROM TURMERIC AS A DRUG CANDIDATE FOR ALZHEIMER’S DISEASE. P.B. Tirupathi Pichiah. The Turmeric. Rhizomatous herbaceous perennial plant Ginger family Used as a spice in Indian, Persian, Thai and Malay dishes, not only in curry, but also in masak lemak, rendang and many more.

★ ★ ★ ★ ★

1.08k views • 56 slides
Patricia S. Steeg, Ph.D. Director, Molecular Therapeutics Program Chief, Women’s Cancers Section, Laboratory of Patholog

Patricia S. Steeg, Ph.D. Director, Molecular Therapeutics Program Chief, Women’s Cancers Section, Laboratory of Patholog

New Molecular Targets for Metastatic Breast Cancer. Patricia S. Steeg, Ph.D. Director, Molecular Therapeutics Program Chief, Women’s Cancers Section, Laboratory of Pathology National Cancer Institute Bethesda, MD. We tend to focus on ER and Her-2. There is “more” !.

★ ★ ★ ★ ★

596 views • 37 slides
Discovery and Molecular Targets

Discovery and Molecular Targets

Discovery and Molecular Targets. Susan Holbeck, Ph.D. National Cancer Institute Developmental Therapeutics Program Information Technology Branch holbecks@mail.nih.gov. NCI-DTP Drug Discovery Resources. NCI panel of 60 human tumor cell lines 2 day 5-dose growth inhibition assay

★ ★ ★ ★ ★

609 views • 32 slides
Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P

Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P

CTOS-Seattle, November 2007. TERAPEUTIC CONSEQUENCES FROM MOLECOLAR BIOLOGY FOR GIST PATIENTS AFFECTED BY NEUROFIBROMATOSIS TYPE 1. Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Mannheim University Hospital, Germany Bonn University Hospital, Germany

★ ★ ★ ★ ★

449 views • 32 slides
Joint FAO/WHO Workshop on fruit and vegetables Aug. 15, 2006. Coex, Seoul

Joint FAO/WHO Workshop on fruit and vegetables Aug. 15, 2006. Coex, Seoul

Joint FAO/WHO Workshop on fruit and vegetables Aug. 15, 2006. Coex, Seoul. Production and consumption of horticultural products in Korea and cancer chemopreventive activity of fruit and vegetables.

★ ★ ★ ★ ★

421 views • 29 slides
Joshua Ko School of Chinese Medicine Hong Kong Baptist University

Joshua Ko School of Chinese Medicine Hong Kong Baptist University

Herbal diterpenoids pseudolaric acid B and triptolide induce growth arrest and apoptosis in colon cancer cells. Joshua Ko School of Chinese Medicine Hong Kong Baptist University. Pseudolaric acid B. Introduction.

★ ★ ★ ★ ★

474 views • 27 slides
Managing Gastrointestinal Side Effects of Targeted Therapies

Managing Gastrointestinal Side Effects of Targeted Therapies

Managing Gastrointestinal Side Effects of Targeted Therapies. Amy Goodrich, MSN, NP-AC The Johns Hopkins Kimmel Cancer Center, Baltimore, MD. General Concepts of GI Toxicity in Cancer Patients.

★ ★ ★ ★ ★

562 views • 22 slides
R&I: Ovarian Cancer Therapeutics in Major Developed Markets

R&I: Ovarian Cancer Therapeutics in Major Developed Markets

The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. Detailed report at: http://www.reportsandintelligence.com/ovarian-cancer-therapeutics-in-major-developed-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market

★ ★ ★ ★ ★

298 views • 10 slides
Aarkstore - Frontier Pharma: Alzheimers Disease - Identifyin

Aarkstore - Frontier Pharma: Alzheimers Disease - Identifyin

The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. For more details : http://goo.gl/WVUmG0

★ ★ ★ ★ ★

233 views • 10 slides
R&I: Psoriasis - Identifying and Commercializing Market

R&I: Psoriasis - Identifying and Commercializing Market

Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Detailed report at: http://www.reportsandintelligence.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market

★ ★ ★ ★ ★

291 views • 9 slides
Frontier:Alzheimers Disease-Identifying Market

Frontier:Alzheimers Disease-Identifying Market

Big Market Research presents this report which covers and includes a brief introduction to AD, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms,the changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline Read The Complete Report On : http://www.bigmarketresearch.com/frontier-pharma-alzheimers-disease-identifying-and-commercializing-first-in-class-innovation-market

★ ★ ★ ★ ★

243 views • 9 slides
Transplantation therapeutics Global Market Forecast

Transplantation therapeutics Global Market Forecast

Frontier Pharma: Transplantation Therapeutics-A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

★ ★ ★ ★ ★

101 views • 9 slides
Liver Cancer-Identifying and Commercializing First-in-Class

Liver Cancer-Identifying and Commercializing First-in-Class

The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market

★ ★ ★ ★ ★

278 views • 8 slides
Multiresistances and Pathogeny factors from Nematodes

Multiresistances and Pathogeny factors from Nematodes

Loire Valley Research Center UMR 1282 - ISP. Multiresistances and Pathogeny factors from Nematodes. Our main research topics. Identification of the molecular targets of AH () in nematodes old and new molecules Decipher the molecular mechanisms involved in AH resistance

★ ★ ★ ★ ★

81 views • 7 slides
Psoriasis - Identifying and Commercializing First-in-Class I

Psoriasis - Identifying and Commercializing First-in-Class I

GBI Research has released the pharma report: “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including safety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful.

★ ★ ★ ★ ★

186 views • 6 slides
Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation - Market overview, size, outlook, g

Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation - Market overview, size, outlook, g

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

★ ★ ★ ★ ★

170 views • 6 slides
Future Market Trends of Obesity Market Till 2021

Future Market Trends of Obesity Market Till 2021

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared.

★ ★ ★ ★ ★

150 views • 5 slides
Parkinson’s Disease Market Forecast & Future Industry Trends

Parkinson’s Disease Market Forecast & Future Industry Trends

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia.

★ ★ ★ ★ ★

242 views • 5 slides
Table 1 Possible molecular targets and corresponding biologic agents in SLE

Table 1 Possible molecular targets and corresponding biologic agents in SLE

Table 1 Possible molecular targets and corresponding biologic agents in SLE. Stohl, W. (2013) Future prospects in biologic therapy for systemic lupus erythematosus Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2013.136.

★ ★ ★ ★ ★

149 views • 1 slides

View Molecular targets PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Molecular targets PowerPoint presentations. You can view or download Molecular targets presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.